[{"address1": "75 State Street", "address2": "Suite 100", "city": "Boston", "state": "MA", "zip": "02109", "country": "United States", "phone": "617 229 6499", "website": "https://www.finchtherapeutics.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company develops FIN-211, a microbiome candidate designed to address the gastrointestinal and behavioral symptoms of autism spectrum disorder; and FIN-524 for the prevention, diagnosis, theragnosis or treatment of diseases in humans, including ulcerative colitis; FIN-525 for the treatment of Crohn's disease; and other microbiome product candidates. The company has collaboration and license agreements with Takeda Pharmaceutical Company Limited; and license agreements with Skysong Innovations LLC, OpenBiome, Arizona State University, and University of Minnesota. Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Boston, Massachusetts.", "fullTimeEmployees": 1, "companyOfficers": [{"maxAge": 1, "name": "Mr. Matthew P. Blischak J.D.", "age": 61, "title": "President, Secretary & CEO", "yearBorn": 1963, "fiscalYear": 2023, "totalPay": 558807, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. James S. Sigler MBA", "age": 63, "title": "Executive Vice President of CMC", "yearBorn": 1961, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "executiveTeam": [], "maxAge": 86400, "priceHint": 2, "previousClose": 12.0, "open": 11.92, "dayLow": 11.7, "dayHigh": 12.1, "regularMarketPreviousClose": 12.0, "regularMarketOpen": 11.92, "regularMarketDayLow": 11.7, "regularMarketDayHigh": 12.1, "payoutRatio": 0.0, "beta": 1.155, "forwardPE": -0.58766395, "volume": 900, "regularMarketVolume": 900, "averageVolume": 1973, "averageVolume10days": 1350, "averageDailyVolume10Day": 1350, "bid": 12.0, "ask": 12.1, "bidSize": 1100, "askSize": 1748, "marketCap": 19429732, "fiftyTwoWeekLow": 10.15, "fiftyTwoWeekHigh": 15.85, "allTimeHigh": 675.0, "allTimeLow": 0.8, "priceToSalesTrailing12Months": "Infinity", "fiftyDayAverage": 12.4242, "twoHundredDayAverage": 12.93633, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 32383732, "profitMargins": 0.0, "floatShares": 896192, "sharesOutstanding": 1605763, "sharesShort": 19195, "sharesShortPriorMonth": 10600, "sharesShortPreviousMonthDate": 1713139200, "dateShortInterest": 1715731200, "sharesPercentSharesOut": 0.012, "heldPercentInsiders": 0.03402, "heldPercentInstitutions": 0.0, "shortRatio": 0.19, "shortPercentOfFloat": 0.0276, "impliedSharesOutstanding": 1617710, "bookValue": 8.855, "priceToBook": 1.3664597, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1719705600, "netIncomeToCommon": -14167000, "trailingEps": -8.8, "forwardEps": -20.59, "lastSplitFactor": "1:30", "lastSplitDate": 1686528000, "enterpriseToEbitda": -1.66, "52WeekChange": -0.014657974, "SandP52WeekChange": 0.13837254, "quoteType": "EQUITY", "currentPrice": 12.1, "recommendationKey": "none", "totalCash": 16035000, "totalCashPerShare": 9.986, "ebitda": -19506000, "totalDebt": 28989000, "quickRatio": 3.594, "currentRatio": 3.872, "totalRevenue": 0, "debtToEquity": 203.875, "revenuePerShare": 0.0, "returnOnAssets": -0.2189, "returnOnEquity": -0.67280996, "grossProfits": 0, "freeCashflow": -15963625, "operatingCashflow": -18055000, "grossMargins": 0.0, "ebitdaMargins": 0.0, "operatingMargins": 0.0, "financialCurrency": "USD", "symbol": "FNCH", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Delayed Quote", "triggerable": false, "customPriceAlertConfidence": "LOW", "shortName": "Finch Therapeutics Group, Inc.", "longName": "Finch Therapeutics Group, Inc.", "marketState": "CLOSED", "regularMarketChangePercent": 0.83333653, "regularMarketPrice": 12.1, "cryptoTradeable": false, "corporateActions": [], "regularMarketTime": 1760731200, "exchange": "PNK", "messageBoardId": "finmb_320858778", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "hasPrePostMarketData": false, "firstTradeDateMilliseconds": 1616160600000, "regularMarketChange": 0.10000038, "regularMarketDayRange": "11.7 - 12.1", "fullExchangeName": "OTC Markets OTCPK", "averageDailyVolume3Month": 1973, "fiftyTwoWeekLowChange": 1.9500008, "fiftyTwoWeekLowChangePercent": 0.1921183, "fiftyTwoWeekRange": "10.15 - 15.85", "fiftyTwoWeekHighChange": -3.75, "fiftyTwoWeekHighChangePercent": -0.23659305, "fiftyTwoWeekChangePercent": -1.4657974, "epsTrailingTwelveMonths": -8.8, "epsForward": -20.59, "fiftyDayAverageChange": -0.32419968, "fiftyDayAverageChangePercent": -0.02609421, "twoHundredDayAverageChange": -0.83632946, "twoHundredDayAverageChangePercent": -0.06464967, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "ipoExpectedDate": "2021-03-19", "displayName": "Finch Therapeutics", "trailingPegRatio": null, "__fetch_time": "2025-10-18"}]